MORE►
Juergen Eckhardt
Left to right: Dr. Shehnaaz Suliman, CEO and board member of ReCode; and David Lockhart, president and chief science officer. [Photos: Jennifer Leahy]
Dallas-Founded Biopharma Firm Raises $120M to Expand its Pipeline
by Kevin Cummings | Jun 29, 2022
ReCode Therapeutics, a biopharmaceutical startup using a non-viral lipid nanoparticle delivery platform for gene therapies, has closed a $120 million extension to a funding round it raised last year to help bring its lead programs to human trials and “follow the science” to target new diseases.
With a research team working out of BioLabs' life sciences facility at Pegasus Park, ReCode aims to grow its global team from about 70 to 100 over the next year.
